'Groundbreaking' AbbVie Suits Test Bold Anti-Generic Tactics
By Jeff Overley · March 27, 2019, 8:43 PM EDT
A trio of trailblazing antitrust lawsuits targeting AbbVie Inc. will force a day of reckoning for some of Big Pharma's most audacious and controversial maneuvers to delay generic and biosimilar competition,...
To view the full article, register now.
Try a seven day FREE Trial
Already a subscriber? Click here to login